International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
-
Int. J. Infect. Dis. · Mar 2021
SARS-CoV-2 seroconversion among 4040 Egyptian healthcare workers in 12 resource-limited healthcare facilities: A prospective cohort study.
We examined Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) seroconversion incidence and risk factors 21 days after baseline screening among healthcare workers (HCWs) in a resource-limited setting. ⋯ Most seroconversions were asymptomatic, emphasizing need for regular universal testing. Seropositivity was three-fold that observed at baseline. Cumulative infections increased nationally by a similar rate, suggesting HCW infections reflect community not nosocomial transmission.
-
Int. J. Infect. Dis. · Mar 2021
Measuring the impact of the COVID-19 outbreak in Ecuador using preliminary estimates of excess mortality, March 17-October 22, 2020.
Ecuador is among the worst-hit countries in the world by the coronavirus disease 2019 (COVID-19) pandemic. In terms of confirmed deaths per million inhabitants, as of October 22, Ecuador ranks fourth in the Americas and ninth worldwide according to data from the World Health Organization. In this report, we estimate excess deaths due to any cause in Ecuador since the start of the lockdown measures on March 17, 2020 until October 22, 2020. ⋯ Our results suggest that the real impact of the pandemic in Ecuador was much worse than that indicated by reports from national institutions. Estimates of excess mortality might provide a better approximation of the true COVID-19 death toll. These estimates might capture not only deaths directly attributable to the COVID-19 pandemic but also deaths from other diseases that resulted from indirect effects of the pandemic.
-
Int. J. Infect. Dis. · Mar 2021
Randomized Controlled TrialOmadacycline versus moxifloxacin in adults with community-acquired bacterial pneumonia.
Community-acquired bacterial pneumonia (CABP) is a major clinical burden worldwide. In the phase III OPTIC study (NCT02531438) in CABP, omadacycline was found to be non-inferior to moxifloxacin for investigator-assessed clinical response (IACR) at post-treatment evaluation (PTE, 5-10 days after last dose). This article reports the efficacy findings, as specified in the European Medicines Agency (EMA) guidance. ⋯ Omadacycline was non-inferior to moxifloxacin for IACR at PTE, with high clinical success across pathogen types and patient subgroups.
-
Int. J. Infect. Dis. · Mar 2021
Multicenter StudyEffectiveness of Oseltamivir in reducing 30-day readmissions and mortality among patients with severe seasonal influenza in Australian hospitalized patients.
Worldwide, seasonal influenza causes significant mortality and poses a significant economic burden. Oseltamivir is an effective treatment, but benefits beyond immediate hospitalization are unknown. ⋯ Early administration of Oseltamivir was associated with a reduction in 30-days readmissions and composite-outcome of 30-day readmissions and mortality in adult hospitalized influenza patients when compared to delayed/no-treatment.
-
Int. J. Infect. Dis. · Mar 2021
Effects of COVID-19 on mortality: A 5-year population-based study in Oman.
Mortality surveillance provides a crucial method for monitoring disease activity. Coronavirus disease 2019 (COVID-19) can cause excess mortality both directly and indirectly by increasing deaths from other diseases. The aim of this study was to investigate the effects of COVID-19 on mortality in Oman. ⋯ The COVID-19 pandemic has resulted in a 15% increase in all-cause mortality in Oman, mainly as a result of deaths from COVID-19. However, unclassified deaths, deaths due to respiratory diseases and deaths due to infectious diseases have also increased, enforcing the need for a holistic approach and appropriate coordination of health services during such health crises.